The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study

Figures & data

Table 1 Characteristics of subjects

	Males (n=10)	Females (n=10)
Age (years)	42.5 (9.0)	43.3 (12.4)
Height (cm)	167.9 (5.4)	154.7 (2.9)*
Body weight (kg)	72.2 (9.0)	55.1 (6.3)*
Duration of illness (years)	15.0 (6.6)	14.9 (5.2)
Duration of current medication (months)	26.4 (11.2)	27.0 (13.1)
Antipsychotic dose (mg/day)
Paliperidone	7.7 (3.2)	7.7 (3.2)
Risperidone	6	4.3 (1.2)
Prolactin levels (ng/mL)
Before terguride	28.8 (18.0)	82.3 (37.1)**
After terguride	26.2 (13.1)	56.5 (28.5)**
Adverse event (number)
Anxiety	0	2
Agitation	2	1
Insomnia	0	1
Hallucination	1	2
Sedation	1	1

Notes: Data include mean (standard deviation).

* P<0.001, compared with males.

** P<0.01, compared with males.

Figure 1 Individual changes in prolactin concentrations before and after the adjunctive administration of terguride in males (left) and females (right).

Abbreviation: ns, not significant.

Figure 2 Correlations between the ratio of change for prolactin and baseline prolactin in males (left) and females (right).

Abbreviation: ns, not significant.